spacer
home > ebr > winter 2002 > new challenges in physiogenomics
PUBLICATIONS
European Biopharmaceutical Review

New Challenges in Physiogenomics

Organising, validating and selecting the relevant information is the key to making the right decisions during drug, and other, development. Understanding complex disease pathways by observing the function and interaction of genes (physiogenomics), and discovering new targets and lead candidates has become a major challenge now that massive amounts of information are available through the various high-throughput technologies.This article discusses new tools, including bioinformatics, that overcome existing limitations such as reproducibility, sensitivity and specificity for data analysis, disease space identification, drug development and patient clustering. In the genomic age, the rapid discovery of new therapeutic strategies for multi-factorial diseases relies on the identification and comparison of correlates and cross talks between functional pathways in human and animal models. Understanding these pathways that drive the progression of complex pathologies at cellular and molecular levels, is now perceived as the new challenge of modern physiogenomics.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Nora Benhabilès, Director of Bioinformatics, and Professor Gérard Marguerie, Chief Scientific Officer, at CliniGenetics Dr Nora Benhabilès received her PhD in Molecular Biophysics from the University Pierre et Marie Curie (Paris VI). She worked in several leading European bioinformatics centres before joining CliniGenetics.
Dr Benhabilès is a recognised expert in molecular modelling, structural genomics and statistical methods, and has worked on protein folding, protein sequence analysis, protein structure prediction and molecular dynamics on DNA. In particular, she is active in setting up clustering methods and neural networks applied to post-genomics data. She is an adjunct Professor at the University of Paris teaching molecular modelling, bioinformatics and programming.

Professor Gérard Marguerie holds a PhD in Biophysics and Cell Biology. He is a former Director of Research at the National Center for Scientific Research (CNRS). He then spent three years at the Scripps Clinic in San Diego and was appointed as Director of an INSERM unit in Haematology on returning to France.

Professor Marguerie then took a CEA (Atomic Energy Agency) appointment as Director of the Department of Structural and Molecular Biology at the Nuclear Centre of Research in Grenoble. He was also appointed as the Co-Director of the National Programme on Structural Biology. Professor Marguerie was a substitute Director of the Life Sciences Division of the Atomic Energy Agency, Head of a Functional Genomic Research Unit, and Professor at Evry University (Paris) in cellular biology.


spacer
Dr Nora Benhabilès
spacer
spacer
spacer
Professor Gérard Marguerie
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita

MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >>

White Papers

Choosing the Right CMO for HPAPI Manufacturing

AMRI

Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement